• FDA Retreats From Earlier Advocacy of COI Rule Changes

    US Food and Drug Administration (FDA) Commissioner Margaret Hamburg retreated from her earlier advocacy of changing conflict-of-interest (COI) rules at a House Appropriations Committee hearing 1 February, reports Genetic Engineering & Biotechnology News (GEN) . "We don't, at the moment, see major areas where a legislative fix is required," said Hamburg. The remarks were seemingly in contrast to remarks made July 2011 before the public advocacy group Public Cit...